Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
N. Wagle,Caroline M. Emery,9 Authors,L. Garraway
2011 · DOI: 10.1200/JCO.2010.33.2312
Journal of Clinical Oncology · 986 Citations
TLDR
The MEK1(C121S) mutation was shown to increase kinase activity and confer robust resistance to both RAF and MEK inhibition in vitro, and the use of emerging technologies in a manner that may accelerate personalized cancer medicine is illustrated.